







an Open Access Journal by MDPI

The Role of Immunity in the Tumor Microenvironment

Guest Editor:

Dr. Nand K Roy

La Jolla Institute for Immunology, California, CA, USA

Deadline for manuscript submissions:

15 July 2024

Message from the Guest Editor

It is now well established that the tumor microenvironment plays a tremendous role in cancer progression and regulating therapeutic response. Of all the therapeutic modalities affected by the TME, immunotherapies are also influenced by the participation of different regulatory molecules from immune cells and components of the TME. The latest developments in the field of immunology have significantly improved the efficacy of immunotherapies, such as monoclonal antibody (MAB) therapy, immune checkpoint blockade (ICB) therapy, vaccines, CAR-T therapy, etc., against cancer cells. However, the understanding of the immune system in the TME still requires an in-depth understanding as it is now well recognized that the presence of different innate and adaptive immune cells in the TME can provide both proand anti-tumorigenic immunity against cancer cells. Thus, this Special Issue invites manuscripts in the form of original research articles, reviews, etc., related to the role of immunity in the TME to ultimately broaden the understanding of how to target cancer cells efficiently.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us